ECTRIMS 2017
Scientific Summaries
ECTRIMS 2017
Scientific Summaries
The 2017 European Committee for Treatment and Research for Multiple Sclerosis (ECTRIMS) annual meeting will be held at Le Palais des Congrès de Paris in France from October 25-28. We have selected a number of major presentations that have the potential to improve MS outcomes.
High Efficacy DMTs Reduce Relapses With Early Use
November 3, 2017Should clinicians prescribe high efficacy DMTs for patients with RRMS shortly after diagnosis or reserve them for use once they develop resistance to first-line therapies? A new study from ECTRIMS 2017 may have found an answer.
Two Drugs Reduce Conversion to SPMS
November 3, 2017New research presented at the 2017 ECTRIMS conference has identified two therapies that appear to extend or even prevent the time it takes for RRMS to transition to SPMS.
Biomarker Predicts Conversion From CIS to MS
October 31, 2017New research presented at the 2017 ECTRIMS conference indicates that a test of cerebrospinal fluid could identify which patients are greater risk of CIS to MS progression more accurately than current methods.
Siponimod Slows Progression in SPMS
October 30, 2017Recent research suggests a new immunomodulator could give these patients with secondary progressive multiple sclerosis (SPMS) another alternative to previous treatments.
New Therapy Found to be Safe and Effective for RRMS
October 26, 2017Results of the RADIANCE trial indicate that a new therapy option for patients with RRMS may be on the horizon, according to a study presented at ECTRIMS 2017.
Education Level Predicts Memory Loss in Progressive MS
October 26, 2017Researchers find an answer that helps explain cognitive impairment in patients with progressive multiple sclerosis.
New Analysis Supports Ocrelizumab Safety
October 26, 2017Researchers presented updated safety information for ocrelizumab for patients with primary progressive MS or relapsing forms of the disease.
Could the Innate Immune System Provide a Pathway to Treat PPMS?
October 25, 2017New ECTRIMS 2017 study finds that the innate immune system could play a critical role in the development of multiple sclerosis.
Intensive Neurorehabilitation Improves Treatment Outcomes in MS
October 25, 2017New ECTRIMS 2017 study finds that not treating depression and fatigue in neurorehabilitated patients with progressive multiple sclerosis could have dire consequences.